ProSci

GALE Antibody

Product Code:
 
PSI-26-862
Product Group:
 
Primary Antibodies
Supplier:
 
ProSci
Host Type:
 
Rabbit
Antibody Clonality:
 
Polyclonal
Regulatory Status:
 
RUO
Target Species:
 
Human
Applications:
  • Enzyme-Linked Immunosorbent Assay (ELISA)
  • Western Blot (WB)
Storage:
 
For short periods of storage (days) store at 4˚C. For longer periods of storage, store GALE antibody at -20˚C. As with any antibody avoid repeat freeze-thaw cycles.
1 / 1
Antibody used in WB on Human Liver at 0.2-1 ug/ml.
❮❯

Antibody used in WB on Human Liver at 0.2-1 ug/ml.

No additional charges, what you see is what you pay! *

CodeSizePrice
PSI-26-862-100ul100ul£662.00
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 14-21 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • Show All

Further Information

Additional Names:
GALE, SDR1E1
Application Note:
GALE antibody can be used for detection of GALE by ELISA at 1:312500. GALE antibody can be used for detection of GALE by western blot at 1 μg/mL, and HRP conjugated secondary antibody should be diluted 1:50,000 - 100,000.
Background:
GALE is an UDP-galactose-4-epimerase which catalyzes two distinct but analogous reactions: the epimerization of UDP-glucose to UDP-galactose, and the epimerization of UDP-N-acetylglucosamine to UDP-N-acetylgalactosamine. The bifunctional nature of the enzyme has the important metabolic consequence that mutant cells (or individuals) are dependent not only on exogenous galactose, but also on exogenous N-acetylgalactosamine as a necessary precursor for the synthesis of glycoproteins and glycolipids. Mutations in this gene result in epimerase-deficiency galactosemia, also referred to as galactosemia type 3, a disease characterized by liver damage, early-onset cataracts, deafness and mental retardation, with symptoms ranging from mild ('peripheral' form) to severe ('generalized' form). This gene encodes UDP-galactose-4-epimerase which catalyzes two distinct but analogous reactions: the epimerization of UDP-glucose to UDP-galactose, and the epimerization of UDP-N-acetylglucosamine to UDP-N-acetylgalactosamine. The bifunctional nature of the enzyme has the important metabolic consequence that mutant cells (or individuals) are dependent not only on exogenous galactose, but also on exogenous N-acetylgalactosamine as a necessary precursor for the synthesis of glycoproteins and glycolipids. Mutations in this gene result in epimerase-deficiency galactosemia, also referred to as galactosemia type 3, a disease characterized by liver damage, early-onset cataracts, deafness and mental retardation, with symptoms ranging from mild ('peripheral' form) to severe ('generalized' form). Multiple alternatively spliced transcripts encoding the same protein have been identified.
Background References:
  • Chhay, J.S., (2008) J. Inherit. Metab. Dis. 31 (1), 108-116.
Buffer:
Purified antibody supplied in 1x PBS buffer with 0.09% (w/v) sodium azide and 2% sucrose.
Concentration:
batch dependent
Conjugate:
Unconjugated
Immunogen:
Antibody produced in rabbits immunized with a synthetic peptide corresponding a region of human GALE.
NCBI Gene ID #:
2582
NCBI Official Name:
UDP-galactose-4-epimerase
NCBI Official Symbol:
GALE
NCBI Organism:
Homo sapiens
Physical State:
Liquid
PREDICTED MOLECULAR WEIGHT:
38 kDa
Protein Accession #:
NP_001008217
Protein GI Number:
56118217
Purification:
Antibody is purified by peptide affinity chromatography method.
Swissprot #:
Q14376
User NOte:
Optimal dilutions for each application to be determined by the researcher.